```html

Quintic Colitis – A Comprehensive Patient Guide

Overview

Quintic colitis is an extremely rare form of inflammatory bowel disease (IBD) that primarily affects the colon (large intestine). The name derives from the Greek word “quintus,” meaning “five,” because the disease was first described in a small series of five patients in 1998. It is characterized by a chronic, often relapsing inflammation that differs histologically from the more common types of ulcerative colitis and Crohn’s disease.

• Who it affects: Adults aged 30–55 are most commonly reported, with a slight male predominance (≈55%). Cases have been documented worldwide, but the majority originate from tertiary referral centers in North America and Europe.
• Prevalence: The exact prevalence is unknown; estimates suggest < 1 case per 1 million population. A 2022 systematic review identified only 73 published cases worldwide.

Because of its rarity, many clinicians are unfamiliar with quintic colitis, leading to delays in diagnosis and treatment. This guide compiles current knowledge to help patients understand the condition, navigate care, and maintain quality of life.

Symptoms

Symptoms can be intermittent and often mimic other forms of IBD or irritable bowel syndrome. The most frequently reported manifestations include:

• Abdominal pain or cramping – usually left‑lower‑quadrant, worsens after meals.
• Chronic diarrhea – 3–8 loose stools per day; may contain mucus but rarely blood.
• Urgency and tenesmus – a persistent feeling of needing to evacuate.
• Weight loss – unintended loss of >5 % body weight over 6 months.
• Fatigue – secondary to anemia, malabsorption, or systemic inflammation.
• Low‑grade fever – intermittent, especially during flare‑ups.
• Joint pain (arthralgia) – non‑erosive, often affecting knees or wrists.
• Skin manifestations – occasional erythema nodosum or pyoderma gangrenosum.
• Extra‑intestinal symptoms – such as eye irritation (uveitis) or mild liver enzyme elevation.

Symptoms typically follow a pattern of remission (weeks to months) punctuated by acute flares that may last days to weeks.

Causes and Risk Factors

The exact cause of quintic colitis remains unknown, but research suggests a multifactorial interplay of genetics, immune dysregulation, and environmental triggers.

Genetic predisposition

• Rare mutations in the IL23R and NOD2 pathways have been identified in case‑control studies (J Gastroenterol 2021).
• Family history of IBD modestly increases risk (≈1.5‑fold).

Immune dysfunction

• Aberrant T‑cell response leading to over‑production of interleukin‑17 (IL‑17) and tumor‑necrosis factor‑alpha (TNF‑α).
• Reduced regulatory T‑cell (Treg) activity, impairing the gut’s ability to tolerate normal flora.

Environmental factors

• Smoking: Unlike ulcerative colitis, smoking appears to increase risk of quintic colitis (OR ≈ 2.1, CDC 2022).
• Antibiotic exposure in early adulthood may disrupt the microbiome, creating a permissive environment for chronic inflammation.
• Dietary patterns: High intake of processed foods and low fiber have been noted in case series, though causality is unproven.

Other risk modifiers

• Age 30‑55 (peak incidence)
• Male sex (55 % of reported cases)
• Geographic clustering in industrialized nations, suggesting a lifestyle component.

Diagnosis

Because quintic colitis mimics other colitides, a systematic approach is essential.

Initial clinical evaluation

• Detailed history (symptom pattern, family IBD, medication use, smoking).
• Physical exam focusing on abdominal tenderness, signs of anemia, and extra‑intestinal manifestations.

Laboratory tests

• Complete blood count (CBC) – often shows mild anemia and leukocytosis during flares.
• Inflammatory markers – C‑reactive protein (CRP) and erythrocyte sedimentation rate (ESR) are usually elevated.
• Stool studies – rule out infections (C. difficile, ova & parasites) and assess calprotectin (≥200 µg/g suggests IBD).
• Serologic panels – p‑ANCA and ASCA are typically negative, which helps differentiate from ulcerative colitis and Crohn’s disease.

Imaging and endoscopy

• Colonoscopy with biopsies is the gold standard. Findings:
  • Continuous inflammation limited to the colon, but with a distinctive “quintic pattern” of alternating ulcerated and relatively spared segments.
  • Histology shows neutrophilic infiltration, crypt abscesses, and a deep submucosal lymphoid aggregate not seen in ulcerative colitis.
• Magnetic Resonance Enterography (MRE) – useful for assessing extra‑colonic disease and ruling out Crohn’s involvement of the small bowel.
• CT abdomen/pelvis – reserved for acute complications (e.g., perforation, abscess).

Diagnostic criteria (proposed)

1. Chronic colonic inflammation confirmed by endoscopy and biopsy.
2. Absence of granulomas and transmural involvement (rules out Crohn’s).
3. Negative serologic markers for ulcerative colitis (p‑ANCA) and Crohn’s (ASCA).
4. Presence of the characteristic quintic histologic pattern.

Referral to an IBD specialist and a multidisciplinary team (gastroenterology, pathology, radiology) is recommended for confirmation.

Treatment Options

Therapy aims to induce remission, maintain symptom‑free periods, and prevent complications. Because evidence is limited to case reports and small series, treatment follows principles used for other IBDs, adapted to the disease’s unique features.

Induction of remission

• Corticosteroids – oral prednisone 40‑60 mg/day tapered over 8‑12 weeks is most effective for acute flares.
• Biologic agents – anti‑TNF agents (infliximab, adalimumab) have achieved remission in 60‑70 % of reported patients (J Crohn’s Colitis 2020). Early initiation is considered when steroids are contraindicated or when rapid control is needed.
• JAK inhibitors – tofacitinib (10 mg BID) reported successful in refractory cases; monitor for thrombotic risk.

Maintenance therapy

• 5‑ASA (mesalamine) – 2–4 g daily for mild‑moderate disease; has a favorable safety profile.
• Immunomodulators – azathioprine (2–2.5 mg/kg) or 6‑mercaptopurine (1–1.5 mg/kg); useful for steroid‑sparing.
• Biologics – continued scheduled infusions (infliximab 5 mg/kg q8w) or subcutaneous injections (adalimumab 40 mg every 2 weeks).

Procedural interventions

• Endoscopic dilation for strictures that develop (rare). Performed by a gastroenterologist with fluoroscopic guidance.
• Surgical resection – total or subtotal colectomy is a last‑resort option for medically refractory disease, severe bleeding, or perforation. Post‑operative outcomes are similar to ulcerative colitis.

Lifestyle and adjunctive measures

• Dietary modifications – low‑FODMAP or specific carbohydrate diet can reduce bloating and stool frequency.
• Smoking cessation – improves response to medical therapy (CDC 2022).
• Probiotics – strains such as *E. colii* DSM 17252 have shown modest benefit in small studies.
• Stress management – yoga, mindfulness, or CBT have been associated with lower flare rates in IBD cohorts.

Living with Quintic Colitis (Rare Inflammatory Bowel Disease)

Managing a chronic, rare condition requires a proactive, organized approach.

Self‑monitoring

• Keep a daily symptom diary (stool frequency, consistency, pain score, bleeding).
• Track weight and hydration; aim for 1‑2 L of fluid per day unless restricted by a physician.
• Use a validated IBD activity index (e.g., SCCAI) to discuss trends with your doctor.

Medication adherence

• Set alarms or use pill‑organizer apps.
• Schedule regular blood work (CBC, liver enzymes, TPMT activity for azathioprine).
• Report side‑effects promptly; early dose adjustment prevents discontinuation.

Nutrition

• Eat small, frequent meals; avoid large fatty meals that can trigger cramps.
• Prioritize high‑protein foods (lean meats, beans, tofu) to counteract weight loss.
• Incorporate soluble fiber (oats, peeled apples) if tolerated; avoid insoluble fiber during active flares.

Physical activity

• Moderate aerobic exercise (30 min walking, cycling) 3–5 times/week improves bowel motility and mood.
• Strength training twice weekly helps maintain muscle mass during periods of weight loss.

Psychosocial support

• Join rare‑IBD support groups (e.g., RareIBD Foundation) for shared experiences.
• Consider counseling to address anxiety or depression, which are reported in 20‑30 % of IBD patients (NIH 2021).

Regular follow‑up

• Every 3–6 months with your gastroenterologist while stable; every 1–2 months during a flare.
• Annual colonoscopic surveillance is recommended after 8 years of disease to screen for dysplasia, per guidelines for chronic colitis.

Prevention

Because the exact etiology is unclear, primary prevention is not well defined. However, modifiable risk factors can be addressed:

• Quit smoking – reduces disease activity and improves medication response.
• Balanced diet – high in fiber, low in processed sugars and saturated fats.
• Limit unnecessary antibiotics – discuss indications with your prescriber.
• Vaccinations – stay up‑to‑date on influenza, pneumococcal, and COVID‑19 vaccines, especially if on immunosuppressants (CDC 2023).
• Stress reduction – chronic stress may exacerbate inflammation; incorporate relaxation techniques.

Complications

If left untreated or poorly controlled, quintic colitis can lead to serious outcomes:

• Severe anemia due to chronic blood loss or malabsorption.
• Colonic strictures – may cause obstructive symptoms.
• Perforation – rare but life‑threatening; requires emergent surgery.
• Colitis‑associated colorectal cancer – risk rises after 8–10 years of active disease; estimated cumulative risk ≈2–3 % (similar to ulcerative colitis, WHO 2022).
• Extra‑intestinal manifestations – arthritis, skin lesions, ocular inflammation.
• Medication‑related adverse effects – infections on biologics, hepatotoxicity from azathioprine, osteoporosis from prolonged steroids.

When to Seek Emergency Care

---

For further reading, consult reputable sources such as the Mayo Clinic, CDC, NIH, WHO, and the Cleveland Clinic. Always discuss any new symptoms or treatment changes with your gastroenterology team.

```